University of California

Lawrence Livermore National Security, LLC

Arizona Board of Regents, a Body Corporate

Selectide Corporation

Purdue Research Foundation

University of South Florida

The University of Arizona

The United States Government as Represented by the Department of Veterans Affairs

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Kit S Lam

Juntao Luo

Ruiwu Liu

Yuanpei Li

Sydney E Salmon

Chong-Xian Pan

Matthew A Coleman

Paul Henderson

Wei He

Wei Yao

Nancy E Lane

Michal Lebl

Hongyong Zhang

Kai Xiao

Olulanu H Aina

Aijun Wang

Nikolai Sepetov

Derick H Lau

Victor Krchnak

Wenwu Xiao

Peter Kocis

Yan E Wang

Alyssa Panitch

Carlito Bangeles Lebrilla

William S Dalton

Lori Hazlehurst

R Holland Cheng

Mark J Kurth

Li Xing

Nancy Lane

Anne E Cress

Viktor Krchnak

Lee-way Jin

Izumi Maezawa

Lin Tian

Tzu-yin Lin

Sara Ahadi

Ekama Onofiok

Joyce S Lee

Diana Lac

Richard D Carpenter

Mirela Andrei

Chun Feng

Hyun-Seok Hong

Hyun Joo An

Gaurav Bhardwaj

Suzanne Miyamoto

Siddarth Chandrasekaran

Li Peng

Caihong Feng

Ye Chen-Izu

Alan L Lehman

Emily Michelle Misnick

Gaurav Bharadwaj

Leighton T Izu

Jenny B Lin

Dake Hao

Chongxian Pan

Petr Kocis

Tsung-Chieh Shih

An Hyun Joo Joo

The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R), wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

Apolipoprotein nanodiscs with telodendrimer

The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the αβintegrin on mesenchymal stem cells and for the surface of bone.

Peptides for activation of cell signaling in osteoprogenitor cells

The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R), wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer, each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair

Methods and compositions are provided for hybrid telodendrimers and nanocarriers containing such hybrid telodendrimers.

Hybrid telodendrimers

The present invention provides scaffolds that include a polymer and a cyclic peptide ligand. The peptide ligand increases the attachment of endothelial cells and/or progenitor cells to the scaffold. The present invention also provides engineered tissues that include the provided scaffolds. The present invention also provides coatings that include a coating polymer and a cyclic peptide ligand. The present invention also provides methods of improving endothelialization and vascularization of endothelial cells and/or progenitor cells for tissue regeneration in a subject and of repairing bone defects in a subject, by implanting a provided scaffold.

Engineered scaffolds for vascularized tissue repair

The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

Porphyrin modified telodendrimers

Reversibly crosslinked micelle systems

The present invention provides a nanoparticle including at least one poly(vinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.

Poly(vinyl alcohol) nanocarriers

The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R), wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a polyethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

The present invention provides benzamidazole compounds and methods of using the compounds as galectin-1 inhibitors.

LLS compounds for treatment of cancer

The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.

Functional illumination in living cells

Methods and compositions are described herein for covalently linking an antibody to a molecular payload. Compositions are described herein containing an antibody covalently linked to a molecular payload.

Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin

The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.

Nanocarriers for drug delivery

Provided are compositions and methods employing cells encapsulated within and attached to a hydrogel, e.g., for measuring mechanical strain and/or stress of the cell and for investigating the mechano-chemo-transduction mechanisms at cellular and molecular levels.

Compositions and methods for measuring cellular mechanical stress

Growing community of inventors

Davis, CA, United States of America

Kit S Lam